Apellis Pharmaceuticals Inc’s recently made public that its Former Officer Townsend Adam J. acquired Company’s shares for reported $3.92 million on May 12 ’25. In the deal valued at $17.76 per share,220,961 shares were bought.
Then, Chopas James George sold 183 shares, generating $4,543 in total proceeds. Upon selling the shares at $24.82, the VP/Chief Accounting Officer now owns 47,955 shares.
Before that, Chopas James George bought 183 shares. Apellis Pharmaceuticals Inc shares valued at $4,543 were divested by the Officer at a price of $24.82 per share.
Raymond James downgraded its Apellis Pharmaceuticals Inc [APLS] rating to an Outperform from a a Strong buy in a research note published recently. A number of analysts have revised their coverage, including BofA Securities’s analysts, who decreased its forecast for the stock in early May from “a Buy” to “a Neutral”. Cantor Fitzgerald began covering APLS with “an Overweight” recommendation on April 29, 2025. Goldman revised its rating on December 17, 2024. It rated APLS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -1.37% to $17.28. Over the last five days, the stock has lost -9.62%. Apellis Pharmaceuticals Inc shares have fallen nearly -45.85% since the year began. Nevertheless, the stocks have fallen -59.36% over the past one year. While a 52-week high of $43.99 was reached on 01/07/25, a 52-week low of $16.65 was recorded on 05/07/25. SMA at 50 days reached $21.22, while 200 days put it at $29.21.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 17.08, which if violated will result in even more drops to 16.88. On the upside, there is a resistance level at 17.56. A further resistance level may holdings at 17.83. The Relative Strength Index (RSI) on the 14-day chart is 34.90, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 84.63%. Stochastics %K at 17.48% indicates the stock is a buying.
The most recent change occurred on November 21, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $31 price target.
